Sangamo Therapeutics, Inc. (SGMO) — Financial statements
Income statement, balance sheet, and cash flow for Sangamo Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 40↓31.6% | 58↓67.2% | 176↑58.3% | 111↑0.5% | 111 | |
| Cost of Revenue | 8 | 0.00 | 0.00↓100.0% | 12 | 0.00 | |
| Gross Profit | 32↓44.7% | 58↓67.2% | 176↑77.7% | 99↓10.4% | 111 | |
| Operating Expenses | ||||||
| R&D Expenses | 113↑1.0% | 112↓52.4% | 234↓6.3% | 250↑8.3% | 231 | |
| General & Administrative Expenses | 35↓22.0% | 45↓26.9% | 61↓2.4% | 63↓0.8% | 63 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 35↓22.0% | 45↓26.9% | 61↓2.4% | 63↓0.8% | 63 | |
| Other Expenses | -8↓237.7% | 6↓96.4% | 155↑1380.3% | -12 | 0.00 | |
| Operating Expenses | 140↓13.5% | 162↓64.1% | 450↑49.8% | 300↑2.2% | 294 | |
| Total Costs & Expenses | 148↓8.8% | 162↓64.1% | 450↑44.0% | 313↑6.3% | 294 | |
| Operating Results | ||||||
| Operating Income | -108↓3.9% | -104↑62.1% | -274↓36.1% | -201↓9.8% | -183 | |
| Depreciation & Amortization | 8↓18.8% | 9↓57.8% | 22↑83.3% | 12↓31.4% | 18 | |
| EBITDA | -100↓12.7% | -89↑8.0% | -97↑48.8% | -189↓14.2% | -166 | |
| EBIT | -108↓9.7% | -98↑17.3% | -119↑40.9% | -201↓9.8% | -183 | |
| Interest & Other Income | ||||||
| Net Interest Income | 1↓77.8% | 6↓47.2% | 11↑17.7% | 9↑76.4% | 5 | |
| Interest Income | 1↓77.8% | 6↓47.2% | 11↑17.7% | 9↑76.4% | 5 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -6↑96.4% | -155 | 0.00 | 0.00 | |
| Other Income / Expenses | -15↓364.4% | 6↓47.2% | 11↑17.7% | 9↑76.4% | 5 | |
| Income Before Tax | -124↓25.9% | -98↑62.7% | -263↓37.0% | -192↓7.8% | -178 | |
| Income Tax Expense | -0.57↓240.1% | -0.17↑96.7% | -5↓1282.3% | 0.43↑40.2% | 0.31 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -123↓25.5% | -98↑62.0% | -258↓34.1% | -192↓7.8% | -178 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -123↓25.5% | -98↑62.0% | -258↓34.1% | -192↓7.8% | -178 | |
| Bottom-Line Net Income | -123↓25.5% | -98↑62.0% | -258↓34.1% | -192↓7.8% | -178 | |
| EPS (Basic) | -0.44↑10.2% | -0.49↑66.9% | -1.48↓18.4% | -1.25↓1.6% | -1.23 | |
| EPS (Diluted) | -0.44↑10.2% | -0.49↑66.9% | -1.48↓18.4% | -1.25↓1.6% | -1.23 | |
| Weighted Average Shares | 280↑38.9% | 202↑15.6% | 174↑13.0% | 154↑6.8% | 145 | |
| Weighted Average Diluted Shares | 280↑38.9% | 202↑15.6% | 174↑13.0% | 154↑6.8% | 145 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.